The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

September 08, 2023

Loretta J. Nastoupil, MD, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.

September 07, 2023

Hagop M. Kantarjian, MD, discusses the predictive value of early landmark cytogenetic or molecular responses to ponatinib in heavily pretreated patients with chronic-phase chronic myeloid leukemia.

September 06, 2023

The addition of the TKI ponatinib to reduced-intensity chemotherapy led to an increase in minimal residual disease-negative complete remission rate at the end of induction compared with imatinib among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

September 05, 2023

Natalie Vokes, MD, discusses emerging biomarkers in non–small cell lung cancer, specifically highlighting the promise of HER3-targeted therapy.

September 05, 2023

Expert hematologist-oncologists consider how the PhALLCON trial elucidates the safety of ponatinib in Ph+ ALL, highlighting comparable toxicity rates and favorable efficacy endpoints.

September 05, 2023

Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss promising results and regulatory progress for ponatinib in frontline Philadelphia-positive acute lymphoblastic leukemia treatment.

August 30, 2023

Funda Meric-Bernstam, MD, discusses the safety of CBX-12 and exploring dosage of the agent.

August 29, 2023

Arvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.

August 29, 2023

Xiuning Le, MD, PhD, discusses ongoing and future investigations with osimertinib and chemotherapy in patients with metastatic lung cancer.

August 29, 2023

Key opinion leaders review the evolution of Ph+ ALL treatment, from Hyper-CVAD to novel TKIs, blinatumomab, and deintensification, improving remission rates and survival.

August 29, 2023

Leading experts Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss diagnostic challenges, evolving treatments, and prognosis in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

August 29, 2023

Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.

August 29, 2023

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.

August 24, 2023

In this episode of "How This Is Building Me," Drs Camidge and Vokes discuss the span of countries and institutions along Dr Vokes’ journey to MD Anderson Cancer Center, how Dr Vokes balances research and work in the clinic, and how the correct mentors can help shape career paths in oncology.

August 24, 2023

Elias Jabbour, MD, outlines additional findings from PhALLCON and their clinical implications for patients with Philadelphia chromosome-positive ALL

August 24, 2023

Panelists wrap up their discussion on HER2+ breast cancer by summarizing the most exciting recent advances in the field and their hopes for the future of treatment.

August 22, 2023

Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.

August 22, 2023

A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.

August 17, 2023

Expert medical oncologists take a step into the future and discuss developments within the adjuvant setting of early-stage breast cancer they are most excited about.

August 17, 2023

Dr Kaklamani presents a profile of a patient with HER2+ breast cancer and liver metastases who had disease progression after first-line chemotherapy and a solitary new brain metastasis after second-line T-DM1.